Zimbabwe has rejected a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on sensitive information.
This rejection was revealed after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesman has since stated that the United States was seeking biological samples for scientific study and profit but refused to guarantee the benefits from any future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more dialogue to find a agreement suitable to all parties so the country's critical HIV treatment initiative can continue.
Broader Context
This rejection comes after a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were raised about the safety of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance openness and accountability.
Based on reports, 16 nations in Africa have so far signed similar agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our country would provide the raw materials for medical research without any assurance that the end products would be available to our population should a new pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one health agreements were upending structures previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to manage potential global health emergencies.
"This system is intended to ensure that when a country provides its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further discussions with our US partners on how future co-operation might be arranged in a way that respects the independence and dignity of each country."
Health Experts Response
A leading public health body stated it recognised the official position, but suggested that talks must proceed given that a large portion of the country's Aids initiatives were funded by international support.
"If technical issues exist, including those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," the group added.
The situation emphasises the continuing debate between receiving much-needed international aid and safeguarding local interests in an ever more data-driven world.